S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:OCX

OncoCyte (OCX) Competitors

$0.21
0.00 (0.00%)
(As of 06/9/2023 ET)
Compare
Today's Range
$0.21
$0.22
50-Day Range
$0.21
$0.27
52-Week Range
$0.20
$1.27
Volume
168,092 shs
Average Volume
264,272 shs
Market Capitalization
$35.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.11

OCX vs. NYMX, TRIB, ICCC, AWH, BMRA, CDIO, MYMD, TKNO, ACHV, and POCI

Should you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), ImmuCell (ICCC), Aspira Women's Health (AWH), Biomerica (BMRA), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and Precision Optics (POCI). These companies are all part of the "medical" sector.

OncoCyte vs.

OncoCyte (NASDAQ:OCX) and Nymox Pharmaceutical (NASDAQ:NYMX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership.

Nymox Pharmaceutical has a net margin of 0.00% compared to OncoCyte's net margin of -787.97%. OncoCyte's return on equity of -34.08% beat Nymox Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
OncoCyte -787.97% -34.08% -15.49%
Nymox Pharmaceutical N/A -1,589.50% -117.25%

81.2% of OncoCyte shares are held by institutional investors. Comparatively, 0.8% of Nymox Pharmaceutical shares are held by institutional investors. 6.7% of OncoCyte shares are held by company insiders. Comparatively, 54.0% of Nymox Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

OncoCyte has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Nymox Pharmaceutical has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Nymox Pharmaceutical has lower revenue, but higher earnings than OncoCyte.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoCyte$960 thousand36.60-$72.90 millionN/AN/A
Nymox PharmaceuticalN/AN/A-$6.58 million-$0.04-9.75

OncoCyte presently has a consensus target price of $1.11, suggesting a potential upside of 421.81%. Given OncoCyte's higher probable upside, equities analysts clearly believe OncoCyte is more favorable than Nymox Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OncoCyte
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Nymox Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Nymox Pharmaceutical received 149 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 51.55% of users gave Nymox Pharmaceutical an outperform vote while only 12.50% of users gave OncoCyte an outperform vote.

CompanyUnderperformOutperform
OncoCyteOutperform Votes
1
12.50%
Underperform Votes
7
87.50%
Nymox PharmaceuticalOutperform Votes
150
51.55%
Underperform Votes
141
48.45%

In the previous week, OncoCyte had 2 more articles in the media than Nymox Pharmaceutical. MarketBeat recorded 3 mentions for OncoCyte and 1 mentions for Nymox Pharmaceutical. Nymox Pharmaceutical's average media sentiment score of 1.89 beat OncoCyte's score of 0.47 indicating that Nymox Pharmaceutical is being referred to more favorably in the news media.

Company Overall Sentiment
OncoCyte Neutral
Nymox Pharmaceutical Very Positive

Summary

OncoCyte beats Nymox Pharmaceutical on 8 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCX vs. The Competition

MetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$35.14M$2.28B$4.58B$6.28B
Dividend YieldN/A0.79%2.26%6.27%
P/E RatioN/A4.1787.2112.33
Price / Sales36.6083.323,376.1989.01
Price / Cash4.815,760.6393.51115.16
Price / Book0.746.204.715.30
Net Income-$72.90M$10.36M$117.85M$193.31M
7 Day Performance-2.91%-0.86%0.81%1.29%
1 Month Performance-20.09%1.63%1.02%4.61%
1 Year PerformanceN/A-2.58%19.08%5.86%

OncoCyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NYMX
Nymox Pharmaceutical
0 of 5 stars
$0.41
+2.5%
N/A-11.7%$36.90MN/A-10.193Analyst Report
TRIB
Trinity Biotech
1.4956 of 5 stars
$0.96
+2.1%
N/A-21.6%$36.58M$74.78M-0.74543Analyst Report
News Coverage
ICCC
ImmuCell
0 of 5 stars
$5.09
-1.0%
N/A-37.3%$39.45M$18.57M-7.3860
AWH
Aspira Women's Health
1.5741 of 5 stars
$2.78
-7.0%
$30.00
+979.1%
-66.8%$23.16M$8.18M-0.2185Analyst Report
BMRA
Biomerica
0 of 5 stars
$1.30
+0.8%
N/A-59.7%$21.85M$18.87M-2.4166
CDIO
Cardio Diagnostics
2.2338 of 5 stars
$1.35
-6.9%
$8.00
+492.6%
N/A$13.09M$950.000.00N/APositive News
MYMD
MyMD Pharmaceuticals
0 of 5 stars
$1.61
-3.0%
N/A-41.4%$63.55MN/A-4.476Upcoming Earnings
TKNO
Alpha Teknova
2.4803 of 5 stars
$3.90
-0.5%
$9.33
+139.3%
-45.4%$110.06M$41.42M-2.17237Positive News
ACHV
Achieve Life Sciences
1.9987 of 5 stars
$6.28
-2.6%
$18.67
+197.2%
-11.2%$113.30MN/A-1.6716
POCI
Precision Optics
0 of 5 stars
$6.67
+2.6%
N/AN/A$37.61M$20.81M66.70N/AGap Up

Related Companies and Tools

This page (NASDAQ:OCX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -